359 related articles for article (PubMed ID: 26454835)
1. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
[TBL] [Abstract][Full Text] [Related]
3. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
[TBL] [Abstract][Full Text] [Related]
5. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
Webster L; Hjelmström P; Sumner M; Gunderson EW
J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
[TBL] [Abstract][Full Text] [Related]
7. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
Jain K; Jain R; Dhawan A
J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
[TBL] [Abstract][Full Text] [Related]
8. Commentary on Hser et al. (2014): to retain or not to retain-open questions in opioid maintenance therapy.
Soyka M; Hillemacher T
Addiction; 2014 Jan; 109(1):88-9. PubMed ID: 24438113
[No Abstract] [Full Text] [Related]
9. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
Sullivan JG; Webster L
Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.
Hser YI; Evans E; Huang D; Weiss R; Saxon A; Carroll KM; Woody G; Liu D; Wakim P; Matthews AG; Hatch-Maillette M; Jelstrom E; Wiest K; McLaughlin P; Ling W
Addiction; 2016 Apr; 111(4):695-705. PubMed ID: 26599131
[TBL] [Abstract][Full Text] [Related]
12. Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.
Walsh SL; Nuzzo PA; Babalonis S; Casselton V; Lofwall MR
Drug Alcohol Depend; 2016 May; 162():190-8. PubMed ID: 27012435
[TBL] [Abstract][Full Text] [Related]
13. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
Srivastava A; Kahan M; Nader M
Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
[TBL] [Abstract][Full Text] [Related]
14. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
[TBL] [Abstract][Full Text] [Related]
16. Extended-Release Injection vs Sublingual Buprenorphine for Opioid Use Disorder With Fentanyl Use: A Post Hoc Analysis of a Randomized Clinical Trial.
Nunes EV; Comer SD; Lofwall MR; Walsh SL; Peterson S; Tiberg F; Hjelmstrom P; Budilovsky-Kelley NR
JAMA Netw Open; 2024 Jun; 7(6):e2417377. PubMed ID: 38916892
[TBL] [Abstract][Full Text] [Related]
17. Initial response as a predictor of 12-week buprenorphine-naloxone treatment response in a prescription opioid-dependent population.
McDermott KA; Griffin ML; Connery HS; Hilario EY; Fiellin DA; Fitzmaurice GM; Weiss RD
J Clin Psychiatry; 2015 Feb; 76(2):189-94. PubMed ID: 25562462
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
[TBL] [Abstract][Full Text] [Related]
19. Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment.
González-Saiz F; Lozano Rojas O; Trujols J; Alcaraz S; Siñol N; Pérez de Los Cobos J;
Drug Alcohol Depend; 2018 Feb; 183():127-133. PubMed ID: 29247974
[TBL] [Abstract][Full Text] [Related]
20. Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared.
McKeganey N; Russell C; Cockayne L
J Subst Abuse Treat; 2013 Jan; 44(1):97-102. PubMed ID: 22703715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]